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Keratoconus, a common inherited ocular disorder resulting in progressive corneal thinning, is the leading indi-
cation for corneal transplantation in the developed world. Genome-wide association studies have identified
commonSNPs100 kbupstreamofZNF469 strongly associatedwith corneal thickness. Homozygousmutations
in ZNF469 and PR domain-containing protein 5 (PRDM5) genes result in brittle cornea syndrome (BCS) Types 1
and 2, respectively. BCS is an autosomal recessive generalized connective tissue disorder associated with ex-
tremecorneal thinningandahigh riskofcorneal rupture.Some individualswithheterozygousPRDM5mutations
demonstrate a carrier ocular phenotype, which includes a mildly reduced corneal thickness, keratoconus and
blue sclera.We hypothesized that heterozygous variants inPRDM5 and ZNF469 predispose to the development
of isolated keratoconus. We found a significant enrichment of potentially pathologic heterozygous alleles in
ZNF469 associated with the development of keratoconus (P 5 0.00102) resulting in a relative risk of 12.0. This
enrichment of rare potentially pathogenic alleles in ZNF469 in 12.5% of keratoconus patients represents a sig-
nificant mutational load and highlights ZNF469 as themost significant genetic factor responsible for keratoco-
nus identified to date.
INTRODUCTION
Keratoconus (MIM 148300), a common bilateral, progressive
corneal thinning disorder (1), is the leading indication for
corneal transplantation in the developed world, accounting for
25% of the 2500 corneal transplants performed annually in the
UK and a similar proportion of the 32 000 grafts performed
annually in the USA (2). Keratoconus usually arises in the
teenage years and presents a significant health burden in
work-age adults. The minimum incidence is 1 in 2000, but it is
much more common in some ethnic groups (1,3). There is
strong evidence for a heritable component in the development
of keratoconus (4,5).Most studies describe autosomal dominant
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inheritance, with incomplete penetrance or variable expressivity
(4). However, in a genetic modelling study in a multi-ethnicity
population a major recessive genetic defect was the most parsi-
monious (6), although no recessive loci for keratoconus have
been described to date.
The progressive corneal thinning associatedwith keratoconus
[mean central corneal thickness (CCT) 450–500 mm] (7) results
inmyopia and irregular corneal astigmatism. In healthy humans,
CCT is a normally distributed quantitative trait with a mean
of 536+ 31 mm (8), which has an estimated heritability up
to 95% (9). Genome-wide association studies (GWAS) in the
healthy European and Asian populations have identified
CCT-associated loci, with common SNPs upstream of zinc
finger 469 (ZNF469 [MIM 612078]) the most strongly asso-
ciated with CCT (10–14). Mutations in three genes (ZNF469,
COL5A1 and COL8A2) close or within these identified loci
are responsible for rare Mendelian conditions that affect the
corneal structure: brittle corneal syndrome, Ehlers–Danlos syn-
drome and posterior polymorphous corneal dystrophy, respect-
ively (10–12).
Brittle cornea syndrome (BCS) is an autosomal recessive gen-
eralized connective tissue disorder associated with extreme
corneal thinning (220–450 mm) and a high risk of corneal
rupture (15,16). Homozygous mutations in ZNF469 and PR
domain-containing protein 5 [PRDM5 (MIM 614161)] genes
result in BCS Type 1 [BCS1 (MIM 229200)] (17) and BCS
Type 2 [BCS2 (MIM 614170)] (15), respectively. Some indivi-
duals with heterozygous PRDM5 mutations demonstrate a
carrier ocular phenotype which includes a mildly reduced CCT
(480–505 mm), keratoconus and blue sclera (15). In one
family with BCS2, there was a relationship between the severity
and age of onset of keratoconus and PRDM5 mutational status.
Family members with a homozygous PRDM5 mutation (dele-
tion of exons 9–14) developed early and severe keratoconus,
whereas one heterozygous family member developed keratoco-
nus which was clinically milder with a later onset (15). The rela-
tionship between the degree of CCT reduction and the presence
of homozygous or heterozygousmutations inPRDM5 suggested
a dosage effect (15). Although none of the CCT-associated loci
have been mapped to PRDM5, a common SNP (rs10518367)
which is 70 kb upstream of PRDM5 has been associated with
CCT in the European population at the significance level of
P ¼ 8.9 × 1025.
Given that rare ZNF469 and PRDM5 homozygous mutations
result in the extreme corneal thinning disorder (BCS), and that
there was evidence of a carrier ocular phenotype (keratoconus
and corneal thinning) in some individuals with PRDM5 hetero-
zygous mutations, and that common SNPs 100 kb upstream of
ZNF469 are strongly associated with CCT, we undertook
Sanger sequencing of both genes in patients with isolated kera-
toconus; a common ocular disease characterized by progressive
corneal thinning and ectasia.
RESULTS
Heterozygous PRDM5 mutations in carrier individuals from
BCS2 families can result in keratoconus (15), and so the entire
coding region and intron–exon junctions of PRDM5 (exons
1–16) were sequenced in an initial 96 unrelated European
patients with keratoconus. This analysis failed to identify
any pathogenic variants, although eight known SNPs were
detected (rs146268537, rs74320998, rs343192, rs17051264,
rs34666716, rs12499000, rs75893420 and rs55774575). We
therefore proceeded to Sanger sequence ZNF469 in the original
cohort increased with additional keratoconus cases (total
number of cases ¼ 112) of unrelated European patients with
keratoconus from three study centres (Belfast, Leeds and Lau-
sanne). Sequence variants detected by Sanger sequencing were
classified as potentially pathogenic alleles by filtering using (i)
ethnically matched population-specific control data from 784
individuals (outlined in the Materials and Methods); (ii) the
data from dbSNP (Build 137), the May 2012 release of the
1000 Genomes (1KG) Project and the Exome Variant Server
(EVS), NHLBI Exome Sequencing Project (ESP), with no
allele having a minor allele frequency (MAF) .0.1% and (iii)
classifiedasdamagingusing theSorting Intolerant fromTolerant
(SIFT) programme as outlined in theMaterials andMethods and
Figure 2.
From these stringently filtered sequencing data, 12 potentially
pathogenic non-synonymousheterozygousallelesweredetected
in the keratoconus cohort (Table 1) and two in-frame deletions:
c.2904_2909delGTCGGG; p.Ser969_Gly970del and c.9011_
9025delTTCCCGGGAACACCC; p.Leu3004_Thr3008del. In
thekeratoconus cohort followingfiltering, there remained15non-
synonymous classified as tolerated by SIFT which were absent
from control data and had an MAF ,0.1% (Table 2). On the
basis of poor conservation, six of these variants were classified
as polymorphisms leaving nine variants of unknown significance.
We detected 34 non-synonymous and 33 synonymous variants
that were observed in both cases and controls, had an MAF
≥0.1% or were common variants, and were deemed non-
pathogenic (Supplementary Material, Table S1). Overall, this
study identified 34 novel variants (29 non-synonymous and 5 syn-
onymous) that have been submitted to the NCBI dbSNP (Supple-
mentary Material, Table S2). The severity of keratoconus was
graded using the Amsler–Krumeich classification (18,19), and
10 individuals had grade Stage III or above indicating severe
disease (illustrated inFig. 1). Stages III and IVusually require sur-
gical approaches for visual rehabilitation, and three individuals
required corneal transplantation.
As there was the possibility that the alleles identified in the
keratoconus subjects represented chance events, we Sanger
sequenced the complete coding sequence of ZNF469 (13
203 bp) in 96 unaffected and unrelated European control
samples (192 chromosomes) using the same experimental strin-
gency as the case sequencing, anddetectedonenon-synonymous
heterozygous allele (c.1701G . T; p.Gln567His) deemed po-
tentially pathogenic given our filtering criteria (Table 1).
There was a statistically significant enrichment of potentially
pathogenic ZNF469 alleles in the keratoconus subjects (14 var-
iants) compared with the 96 European controls (one variant);
P ¼ 0.00102 [odds ratio (OR) 13.6, relative risk (RR) 12.0].
The allele frequency differences make it impossible for the
rare ZNF469 alleles to be in linkage disequilibrium with the
common variant signal that is within a 53 kb linkage
disequi librium block 117 kb away from the 5′ end of ZNF46,
and this has been replicated in diverse ancestries groups.
The common variant, although strongly associated with
corneal thickness, is not strongly associated with keratoconus
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Table 1. Potentially pathologic ZNF 469 alleles identified in keratoconus and control subjects
Nucleotide changea Amino acid changea Present in 1KG
data [MAF (%)]
Present in EVS
data [MAF (%)]
rs number SIFT prediction
(SIFT score)b
Amsler–Krumeich
classificationc
Corneal
transplantation
Right eye Left eye
Keratoconus cohort
c.290C. T p.Pro97Leu No No rs273585617 Damaging (0) Stage III Stage II No
c.337G . A p.Glu113Lys No No NA Damaging (0) Stage II Stage II No
c.2063C . A p.Thr688Asn No No NA Damaging (0) Stage IV Stage III No
c.2699C . G p.Pro900Arg No No rs273585618 Damaging (0.02) Stage III Stage II Yes; right eye
c.2699C . T p.Pro900Leu No No rs273585618 Damaging (0) Stage II Stage II No
c.2904_2909del GTCGGG p.Ser969_Gly970 del
(in-frame deletion)
No No NA NA Stage IV Stage III Yes; right eye
c.3119A. C p.Lys1040Thr No No rs273585619 Damaging (0) Stage III Stage III Yes; right eye
c.4363G. T p.Ala1455Ser No No rs116532825 Damaging (0.02) Stage I Stage III Yes; left eye
c.5464C . A p.Pro1822Thr Yes (NA) No rs74032866 Damaging (0.04) Stage I Stage I No
c.6095C . A p.Ser2032Tyr No No rs273585623 Damaging (0.05) Stage II Stage III No
c.8912G. T p.Gly2971Val No No rs273585625 Damaging (0.04) Stage III Stage II No
c.9011_9025del
TTCCCGGGAACACCC
p.Leu3004_Thr3008 del
(in-frame deletion)
No No NA NA Stage III Stage II No
c.9047C . T p.Thr3016Met No No rs273585626 Damaging (0.02) Stage II Stage I No
c.11615C. T p.Pro3872Leu No No rs273585630 Damaging (0.03) Stage II Stage III No
Normal controls
c.1701G. T p.Gln567His No No NA Damaging NA NA NA
NA, not available or applicable.
aZNF469 Ensembl transcript ENST00000437464 or NCBI NM_001127464.1 (Build GRCh37/hg19).
bPositions with normalized probabilities of ,0.05 are predicted to be damaging, those ≥0.05 are predicted to be tolerated.
cStages described in Materials and Methods (18,19).
H
u
m
a
n
M
o
lecu
la
r
G
en
etics,
2
0
1
4
,
V
o
l.
2
3
,
N
o
.
2
0
5
5
2
9
{OR 1.25 [95% confidence interval (CI) 1.11–1.40]} (13).
Further functional studies and assays are required to confirm
the pathogenicity of all alleles absent from ethnically matched
controls and the population control data (dbSNP, EVS, 1KG).
DISCUSSION
Mutations in four genes, VSX1 (MIM 605020) (20,21), SOD1
(MIM 147450) (21,22), MIR184 (MIM 613146) (23) and
ZEB1 (MIM 189909) (24), have been implicated in the patho-
genesis of keratoconus in a minority of cases (,4%) (21,25).
Two GWAS have been conducted in keratoconus cohorts
which identified an SNP rs4954218, located near the
RAB3GAP1 gene (MIM 602536) (26), and polymorphisms in
HGF (MIM142409) (27), associatedwith keratoconus suscepti-
bility, but neither study reported genome-wide significant asso-
ciation. The identification of alleles that are predicted to be
potentially pathogenic in 12.5% of keratoconus patients (14/
112) makes ZNF469 the most significant genetic factor respon-
sible for keratoconus identified to date. The small sizes of unre-
lated keratoconus case cohorts favour a candidate genes
approach so that while the P-value obtained for evidence of a
burden of ZNF469 rare damaging variants in the keratoconus
cases is statistically significant, it would not have been in a
genome-wide context.
BCS is a rare recessive connective tissue disorder associated
with consanguinity, with most BCS patients originating from
countries in the Middle East and North Africa (16). ZNF469,
the gene for BCS1, was originally mapped to chromosome
16q24 in a single large Palestinian family and a homozygous
frameshift mutation, (c.9527delG) predicted to result in a pre-
mature termination codon (p.Gln3178ArgfsX23), was subse-
quently reported (17). Five further homozygous ZNF469
mutations have been reported in the literature: a founder muta-
tion in five Tunisian patients (c.5934delA) predicted to result
in a pre-mature termination codon (p.Gly1983AlafsX16),
p.Gln1392X (Syrian origin) (28), p.Phe717SerfsX14 (15),
p.Gln1757X (15) and one homozygous missense mutation
(p.Cys3339Tyr) in a consanguineous Norwegian family (29).
Homozygous mutations in PRDM5 result in BCS2, and in some
families PRDM5 heterozygous gene carriers display an ocular
carrier state that includes a mildly reduced CCT (480–
505 mm), keratoconus and blue sclera (15). Families harbouring
homozygous and heterozygous PRDM5 mutations show a gene
dosage relationship in terms of the degree of CCT reduction and
the severity and age of onset of keratoconus (15). There is no
data available of CCT measurement or corneal topography for
heterozygous carriers of ZNF469 mutations in BCS1 families.
Our data for ZNF469 in the keratoconus population mirrors
that seen in the ocular phenotype of PRDM5 heterozygous
Table 2. ZNF 469 sequence variants identified in keratoconus and control subjects
Nucleotide change Amino acid change rs number Present in 1KG
data [MAF (%)]
Present in EVS
data [MAF (%)]
SIFT prediction Classificationa
Keratoconus cohort
Non-synonymous variants
c.77G. C p.Ser26Thr rs273585616 No No Tolerated Variant of unknown
significance (VUS)
c.1627G. A p.Gly543Ser NA No No Tolerated Polymorphism (Ser common)
c.2297G. A p.Arg766Gln rs144492145 Yes (0.05) No Tolerated Polymorphism
c.3236G. A p.Arg1079Gln NA No No Tolerated Polymorphism (Gln in marmoset)
c.4394C. T p.Pro1465Leu rs369382753 No Yes (0.02) Tolerated Polymorphism
(Leu in rat and mouse)
c.4826G. C p.Arg1609Pro rs273585621 No No Tolerated Polymorphism (Pro in dog)
c.5060G. A p.Arg1687Lys NA No No Tolerated VUS
c.5597A. T p.Gln1866Leu NA No No Tolerated VUS
c.6007G. A p.Glu2003Lys rs273585622 No No Tolerated Polymorphism (Lys in gorilla)
c.6725C. A p.Ser2242Tyr rs273585624 No No Tolerated VUS
c.7527G. C p.Glu2509Asp rs199519673 No Yes (0.090) Tolerated VUS
c.7747G. A p.Glu2583Lys NA No No Tolerated VUS
c.7847G. A p.Arg2616Gln NA No No Tolerated VUS
c.9835A. G p.Thr3279Ala rs273585627 No No Tolerated VUS
c.11101G. A p.Gly3701Ser rs273585629 No No Tolerated VUS
Synonymous variants
c.99G. A p.Pro33Pro rs273585631 No No NA VUS
c.720G. A p.Glu240Glu rs273585632 No No NA VUS
c.2478G. T p.Pro826Pro rs273585634 No No NA VUS
c.6453T. C p.Asp2151Asp NA No No NA VUS
c.10843C. T p.Leu3615Leu NA No No NA VUS
Normal control cohort
Non-synonymous variants
c.10115C. T p.Pro3372Leu NA No No Tolerated VUS
c.11252G. A p.Arg3751Lys NA No No Tolerated Polymorphism (Lys in dog)
Synonymous variants
c.30G. A p.Pro10Pro NA No No NA VUS
c.4281C. A p.Leu1427Leu NA No No NA VUS
aIf predicted to be tolerated using SIFT the conservation of the residue was assessed and if poorly conserved the variant was classified as a polymorphism
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Figure 1.Corneal topography of the 28-year-old European patient from the UKwith a c.3119A. C (p.Lys1040Thr) ZNF469 pathogenic allele (Table 1) using Pen-
tacamcorneal topography;ODindicates right eye andOS left eye.The topography shows theanterior corneal steepening associatedwith keratoconuswith a large cone
centrally in the right eye and paracentrally in the left eye associated with corneal thinning underlying the cones; minimum corneal thickness of 318 mm (OD) and
438 mm (OS). The keratoconus is Stage III in both eyes (Amsler–Krumeich classification) with a best corrected Snellen acuity of 6/36 right and 6/24 left. The
patient subsequently underwent a deep anterior lamellar keratoplasty (corneal transplant) in the right eye.
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carriers. Heterozygous ZNF469 pathological alleles result in
progressive corneal thinning and ectasia producing the keratoco-
nus phenotype. The majority of potentially pathogenic alleles in
the keratoconus cohort were missense variants likely to have a
less deleterious effect on protein function than the ZNF469 trun-
cating mutations commonly associated with BCS1. This further
supports a gene dosage phenomenon wherein homozygous, se-
verely deleterious ZNF469 mutations result in an early-onset
severe and visually devastating ocular phenotype (extreme
corneal thinning, ectasia and spontaneous rupture) (15),
whereas heterozygous, missense ZNF469 mutations result in
corneal thinning, ectasia and keratoconus. Further functional
studies and cell-based assays are required to interrogate the mo-
lecular pathology and mutational mechanisms associated with
these potentially pathogenic ZNF469 alleles.
ZNF469 is a 3925 amino acid evolutionarily poorly conserved
C2H2 zinc finger (C2H2-ZNF) protein of unknown function
(30). C2H2-ZNF genes constitute the largest class of transcrip-
tion factors in humans making up 2% of all the human genes
and represent the second largest gene family in humans (30).
The first identified members of the C2H2-ZNF family were
Xenopus TFIIIA and Drosophila Kruppel, and thus genes of
this family are often called ZNF genes of the TFIIIA or
Kruppel type (30–32). Most C2H2-ZNF genes code for tran-
scription factors which can bind DNA, RNA, DNA–RNA
hybrids and proteins (32). The physiological role of ZNF469 is
not well established, but there is evidence that ZNF469 regulates
extra-cellular matrix development and maintenance (15).
ZNF469 shows 30% sequence similarity to the helical parts of
COL1A2 (MIM 120160), COL1A1 (MIM 120150) and
COL4A1 (MIM 120130), all of which are highly expressed in
the cornea (17). The cornea is composed of 70% collagen,
mostly collagen Type I, and there is evidence of a dysregulation
of collagen homeostasis in the keratoconic cornea (33,34).
Corneal thinning has been reported in osteogenesis imperfect
(35), which results from mutations in COL1A1 or COL1A2.
We have identified an enrichment of potentially pathogenic
alleles in ZNF469 in patients with keratoconus. Further work
is required to determine the functional impact of these variants,
and the pathways regulated byZNF469which are involved in the
development of keratoconus. Identifying genes responsible for
keratoconus may also provide insights into the genetic basis
for the normal variation in CCT. Decreased CCT has been pro-
posed as a risk factor for primary open-angle glaucoma
[POAG (MIM 137760)], the leading cause of irreversible blind-
ness worldwide affecting .60 million people (36). Individual
patients with a thin cornea have a substantially increased risk
for developing POAG (37,38), and glaucoma patients with a
thin CCT have an increased severity andmore rapid progression
of visual field loss (39). The genetic basis of CCT may provide
insights into the development of glaucoma. Common SNPs
near ZNF469 are the strongest CCT-associated loci, although
the functional role of these SNPs is not known (10–13). The
role ZNF469 plays in the development of POAG, and mainten-
ance of CCT in normal subjects has not been determined. Com-
bining resequencing with GWAS has yielded success in
identifying rare disease-associated variants (40,41). Our study
establishes the significant roleZNF469 plays in the development
of keratoconus.
MATERIALS ANDMETHODS
All studies adhered to the tenets of the Declaration of Helsinki
and were approved by the relevant institutions with all partici-
pants giving written informed consent.
Patients
Clinically affected keratoconus patients of European ethnicity
were recruited as part of ongoing studies from Belfast (Belfast
Health and Social Care Trust, UK), Leeds (St. James’s
Figure 2. Hierarchical flow diagram of filtering process performed on sequence variants identified in ZNF469 in keratoconus cohort by Sanger sequencing.
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University Hospital, Leeds, UK) and Lausanne (Jules-Gonin
Eye Hospital, Lausanne and Institute for Research in Ophthal-
mology, Sion, Switzerland); and genomic DNA was extracted
from peripheral blood leukocytes using commercial kits. The
diagnosis of keratoconus was performed by an experienced oph-
thalmologist based on well-established clinical signs on
slit-lampbiomicroscopyandcycloplegic retinoscopy; andacon-
firmatory videokeratographic map obtained using the Topo-
graphic Modelling System-1 (Computed Anatomy Inc., NY,
USA), Orbscan II (Bausch & Lomb, Salt Lake City, UT, USA)
or the Pentacam (Oculus, Wetzlar, Germany) (20,27). Slit-lamp
biomicroscopywas used to identify the key features of keratoco-
nus including stromal corneal thinning, Vogt’s striae and
Fleischer rings in affected individuals. The oil droplet sign and
scissoring of the red reflex were assessed by retinoscopy per-
formed with a fully dilated pupil. Patients were considered as
having keratoconus if they had at least one clinical sign of the
disease in conjunction with a confirmatory videokeratography
map (20,27). The severity of keratoconus was graded using the
Amsler–Krumeich classification (18,19):
Amsler–Krumeich classification
Stage I Eccentric corneal steppening
Myopia and/or astigmatism ,5.00D
Mean central K readings ,48.00D
Stage II Myopia and/or astigmatism 5.00–8.00D
Mean central K readings ,53.00D
Absence of scarring
Minimal corneal thickness .400 mm
Stage III Myopia and/or astigmatism 8.00–10.00D
Mean central K readings .53.00D
Absence of scarring
Minimal corneal thickness 300–400 mm
Stage IV Refraction not measurable
Mean central K readings .55.00D
Central corneal scarring
Minimal corneal thickness 200 mm
Ethnically matched population-specific control data
All affected and control individuals were of European ethnicity,
and population-specific control data were obtained from three
sources: (i) a total of 96 unrelated individuals (192 chromo-
somes) without ocular disease (aged 60 and over) from the Nor-
thern Irish population (UK) underwent Sanger sequencing; (ii)
exome data from 275 non-glaucomatous individuals from the
Manchester population (UK), which are effectively ethnically
identical to the Leeds population and (iii) normative control
data for 413 normal individuals from Lausanne (Swiss popula-
tion; European) were obtained from the CoLaus study (http://
www.colaus.ch/) (42).
DNA sequencing and statistical analysis
Polymerase chain reaction (PCR) primers for amplification of
the 16 exons and flanking intron sequences of PRDM5 were
designed using Primer3 (v. 0.4.0) software (http://frodo.wi.m
it.edu/primer3/) (43) and are listed in Supplementary Material,
Table S3. PCR and Sanger sequencing of ZNF469 was under-
taken with primers identical to those previously used by Chris-
tensen et al. (29) (personal communication) with adapted
conditions (Supplementary Material, Table S4). Sequencing
resultswere analysedmanually using the sequence analysis soft-
ware SeqScape 2.1.1 (Applied Biosystems, USA). Identified se-
quence variants were described according to the guidelines
published by the Human Genome Variation Society. Variants
were annotated in accordance with Ensembl transcript ENS
T00000437464 or NCBI NM_001127464.1 (Build GRCh37/
hg19). The sequence variants were passed through a series of fil-
tering steps shown in Figure 2.
If the sequencevariantswere present in the ethnicallymatched
population-specific control data, they were excluded. The
remaining sequence variants were required to have an MAF of
,0.1% in the data from dbSNP (Build 137), the May 2012
release of the 1KG Project and the EVS and NHLBI ESP. Fol-
lowing this, the remaining non-synonymous alleles were filtered
usingSIFTwhich can identify if an amino acid substitution influ-
ences protein function resulting in a phenotypic change; classi-
fied as damaging or tolerated (44). SIFT can distinguish
between functionally neutral and deleterious amino acid
changes in mutagenesis studies and on human polymorphisms
(45,46). There are alternative prediction tools that use a combin-
ation ofmethods based on sequence homology, protein structure
information and physicochemical properties of amino acids for
prediction (44). Given that ZNF469 is a poorly characterized
protein with no verified structural homologues, the SIFT algo-
rithm was applied as SIFT computes a combined score derived
from the distribution of amino acid residues observed at a
given position in the sequence alignment and the estimated un-
observed frequencies of amino acid distribution calculated
from a Dirichlet mixture and does not rely on structural or
physiochemical information (44). The conservation of the
affected amino acid across species was analysed using Homolo-
gene (http://www.ncbi.nlm.nih.gov/homologene/) and multiple
sequence alignment with ClustalX (http://www.clustal.org/)
visualized with GeneDoc software (http://www.nrbsc.org/gfx/
genedoc/).
The collapsing method (47) was used to compare the fre-
quency of remaining potentially pathogenic alleles between
case and control subjects with the level of significance set to P
, 0.05. This method involves collapsing genotypes across var-
iants and applying a univariate test which is powerful for analys-
ing rare variants (47). Specifically, each individual was assigned
an indicator variable that takes the value one if the subject carries
at least one potentially pathogenic variant and zero otherwise.
Whether the proportions of individuals with index variable one
differ significantly in cases and controls were tested using a
Fisher exact test on the corresponding contingency table of
indicator variable counts. The estimated OR, RR, 95% CI
and Fisher’s exact P-value were calculated using JavaStat
(http://statpages.org/ctab2x2.html).
Web Resources
1000Genomes Project: http://browser.1000genomes.org/index.
html.
Exome Variant Server, NHLBI Exome Sequencing Project,
Seattle, WA: http://eversusgs.washington.edu/EVS/.
NCBI dbSNP: http://www.ncbi.nlm.nih.gov/snp.
Fisher’s exact test calculations: http://statpages.org/ctab2x2.
html.
Human Molecular Genetics, 2014, Vol. 23, No. 20 5533
Sorting Intolerant from Tolerant (SIFT: http://sift.jcvi.org/.
Online Mendelian Inheritance in Man (OMIM): http://www.
omim.org/.
Homologene: http://www.ncbi.nlm.nih.gov/homologene/.
ClustalX: http://www.clustal.org/.
GeneDoc software: http://www.nrbsc.org/gfx/genedoc/.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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